News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Johnson & Johnson CEO Declines Merit Raise
February 23, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Feb 23 (Reuters) - Johnson & Johnson Chief Executive William Weldon declined a merit increase in his salary for 2009 from last year citing the global economic environment, the company said in a regulatory filing.
Twitter
LinkedIn
Facebook
Email
Print
People
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
July 17, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
July 16, 2025
·
2 min read
·
Heather McKenzie
IN PARTNERSHIP WITH EVOTEC
Webinar: Pharma Industry in Crisis
July 16, 2025
·
1 min read
·
BioSpace Insights
Earnings
J&J Targets $50B Oncology Sales By 2030: Updated
July 16, 2025
·
2 min read
·
Nick Paul Taylor
